½ÃÀ庸°í¼­
»óǰÄÚµå
1193103

Ç÷°ü »öÀü¼ú ½ÃÀå : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2021-2031³â)

Vascular Embolization Market By Product, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Allied Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 282 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ç÷°ü»öÀü¼úÀÇ ¼¼°è ½ÃÀåÀº 2021³â¿¡ 36¾ï 8,273¸¸ ´Þ·¯°¡ µÇ°í, 2022³âºÎÅÍ 2031³â¿¡ °ÉÃÄ CAGR 7.7%·Î ¼ºÀåÇØ, 2031³â¿¡´Â 77¾ï 8,098¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

»öÀü¼úÀ̶ó°í ºÒ¸®´Â ³·Àº ħ½ÀÀûÀÎ °úÁ¤Àº ƯÁ¤ Àå¼ÒÀÇ Ç÷·ù¸¦ ¾ïÁ¦ÇÕ´Ï´Ù. ÀÌ ÀýÂ÷´Â ÁÖº¯ÀÇ Á¤»óÀûÀÎ Ç÷·ù¸¦ À¯ÁöÇϸ鼭 ¼öÇàµÇ¸ç Á¶Á÷À» º¸È£Çϸ鼭 ¹®Á¦°¡µÇ´Â ÃâÇ÷À» ÇØ°áÇÕ´Ï´Ù. Ç÷°üÀÌ ¸·È÷´Â °ÍÀ» »öÀüÁõÀ̶ó°í Çϸç, ÀÇÇÐÀû ÀÌÀ¯·Î ÀǵµÀûÀ¸·Î Ç÷°üÀ» ¸·´Â °ÍÀ» »öÀü¼úÀ̶ó°íÇÕ´Ï´Ù. ÄÚÀÏ »öÀü¼úÀ̶ó°í ºÒ¸®´Â Ä«Å×Å͸¦ »ç¿ëÇÑ Ä¡·á¹ýÀº µ¿¸Æ ³» ºñÁ¤»óÀûÀÎ Ç÷·ù¸¦ Á¤È®ÇÏ°Ô ¸·À» ¼ö ÀÖ½À´Ï´Ù. ±Ý¼ÓÁ¦ÀÇ Æó»ö ÄÚÀÏÀ» ÀåÂøÇÑ Ä«Å×Å͸¦ ÀÌ¿ëÇÏ¿© Åë»ó »çŸ±¸´ÏºÎ¿¡ ÀÖ´Â µ¿¸Æ(´ëÅ𵿸Æ)¿¡ »ðÀÔÇÕ´Ï´Ù.

±×¸®°í ÀüÁø¿¡ ÀÇÇØ ÀÌ»ó Ç÷°ü¿¡ µµ´ÞÇÕ´Ï´Ù. Ç÷·ù¿Í ÇÔ²² ÀüÁøÇÏ¿© Ä«Å×Åͳª ÄÚÀÏÀÌ ´êÁö ¾Ê´Â °÷±îÁö Ç÷°ü ¹Ù´ÚÀÇ ±í¼÷ÀÌ µé¾î°¡´Â °ÍÀ¸·Î ¾×ü »öÀüÁ¦´Â Ç¥Àû Ç÷°üÀ» ä¿ì°í Ç÷°üÀÇ Æó»öÀ» ÀÏÀ¸Å°´Â ´É·ÂÀ» °¡Áø´Ù. ÂøÅ»½Ä dz¼±Àº ´Ù¸¥ »öÀü¼ú¿¡ ºñÇØ dz¼±À» Á¦°ÅÇÒ ¶§±îÁö »öÀüÀÌ °¡¿ªÀûÀ̶ó´Â ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. Å« µ¿¸Æ°ú ´©°øÀ» Áï½Ã, Á¤È®ÇÏ°Ô ¸·À» ¼ö ÀÖ½À´Ï´Ù. ¼¼°èÀÇ Ç÷°ü »öÀü ½ÃÀåÀÇ ¼ºÀåÀº Ç÷°ü ÁúȯÀÇ À¯º´·üÀÇ ³î¶ó¿î Áõ°¡¿¡ ÀÇÇØ ÁÖ·Î ±¸µ¿µÇ°í ÀÖ½À´Ï´Ù. »öÀü ±â¼ú ¹× Á¦Ç°¿¡ ÀÇÇÑ Ç÷°ü Áúȯ Ä¡·á °³¼±ÀÇ Áõ°¡´Â ¶ÇÇÑ Ç÷°ü »öÀü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÑ´Ù.

¶ÇÇÑ, Ç÷°ü Æó»öÀ» À§ÇÑ ºñħ½ÀÀû ÀýÂ÷¿¡¼­ »öÀüÀÇ ¼º°ø·üÀÌ Áõ°¡Çϰí, Á¾·¡ÀÇ ÀýÂ÷ ¹× ´Ù¸¥ ±â¼úÀÇ Áøº¸¿¡ ´ëÇÑ ½ÇÇà°¡´ÉÇÑ ´ë¾ÈÀ¸·Î¼­ÀÇ °¡¿ë¼ºÀº ´õ¿í ½ÃÀåÀ» ±¸µ¿ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼ÀÎÆ® ÁÖµå ¸ÞµðÄÃÀÇ ¾ÚÇ÷¡Ã³ Ç÷¯±× 4´Â ½ÃÀå¿¡¼­ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª Ç÷°ü »öÀü¼ú ºñ¿ëÀÌ ³ô°í ÇÕº´ÁõÀÌ µ¿¹ÝµÇ¾î ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÕ´Ï´Ù. ¶ÇÇÑ, ¾ÏÄ¡·á¿¡ À־´Â È­Çпä¹ýÀ̳ª ¹æ»ç¼±¿ä¹ý µîÀÇ Ä¡·á¹ýÀÌ ¼±È£µÇÁö¸¸, À̰ÍÀº Á¾·¡ÀÇ ¾ÏÄ¡·á¹ýÀÌ ÀϹÝÀûÀ¸·Î ÀÎÁöµÇ°í ÀÖ´Â °Í, ¼±ÁøÀûÀÎ Ä¡·á¹ýÀÌ º¸±ÞµÇ¾î ÀÖÁö ¾ÊÀº °Í , Á¾¾çÀǰ¡ ±âÁ¸ÀÇ Ä¡·á¹ý¿¡¼­ Àüȯ¿¡ ²¨·ÁÇÏ´Â µîÀÌ ÀÌÀ¯ÀÔ´Ï´Ù. ¶ÇÇÑ, »öÀüÁ¦¸¦ À߸øµÈ Àå¼Ò¿¡ À¯Ä¡ÇØ ¹ö¸®¸é, Á¤»óÀûÀÎ Á¶Á÷À¸·ÎºÎÅÍ »ê¼Ò¸¦ »©¾Ñ¾Æ ¹ö¸± À§Ç輺ÀÌ ÀÖ½À´Ï´Ù. À̵éÀº ½ÃÀå ¼ºÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎÀ̵Ǿú½À´Ï´Ù.

¼¼°èÀÇ Ç÷°ü »öÀü¼ú ½ÃÀåÀº Á¦Ç°, ¿ëµµ ¹× ÃÖÁ¾ »ç¿ëÀÚ·Î ±¸ºÐµË´Ï´Ù. Á¦Ç°º°·Î »öÀüÁ¦¿Í »öÀü¿ë ÀåÄ¡·Î ºÐ·ùµË´Ï´Ù. »öÀüÁ¦¿Í »öÀü ÀåÄ¡´Â ¾×ü »öÀüÁ¦¿Í ¸¶ÀÌÅ©·Î ½ºÇǾî·Î ¼¼ºÐÈ­µË´Ï´Ù. ±×¸®°í »öÀü ÀåÄ¡´Â ÄÚÀÏ, ÂøÅ»½Ä dz¼±, »öÀü Ç÷¯±×, Áö¿ø ÀåÄ¡·Î ºÐ·ùµË´Ï´Ù.

ÀÀ¿ë ÇÁ·Î±×·¥º°·Î º¼ ¶§ ½ÃÀåÀº Á¾¾ç, ¸»ÃÊ Ç÷°ü Áúȯ, ºñ´¢±â, ½ÅÀå, ½Å°æ µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â º´¿ø¡¤Áø·á¼Ò, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. Áö¿ªº° ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× À¯·´ÀÇ ³ª¸ÓÁö), ¾Æ½Ã¾ÆÅÂÆò¾ç(ÀϺ», Áß±¹, È£ÁÖ, Àεµ, Çѱ¹ ¹× ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÇ ³ª¸ÓÁö ºÎºÐ) ¹× LAMEA (ºê¶óÁú, ³²¾ÆÇÁ¸®Ä«, »ç¿ìµð¾Æ¶óºñ¾Æ ¹× LAMEAÀÇ ³ª¸ÓÁö)¿¡ °ÉÃÄ ºÐ¼®µÇ¾ú½À´Ï´Ù. ¼¼°è Ç÷°ü »öÀü ½ÃÀå¿¡¼­ ÀÛµ¿ ÁÖ¿ä ¼±¼ö´Â Abbott ¿¬±¸¼Ò, Balt Group, Boston Scientific Corporation, Cook Medical, Johnson and Johnson, Kaneka Corporation, Medtronic Plc, Merit Medical, Stryker Corporation ¹× Terumo Medical CorporationÀÔ´Ï´Ù.

ÀÌÇØ°ü°èÀÚ¸¦ À§ÇÑ ÁÖ¿ä ÀÌÁ¡

  • º» º¸°í¼­´Â 2021³âºÎÅÍ 2031³â±îÁöÀÇ Ç÷°ü »öÀü¼ú ½ÃÀå ºÐ¼®ÀÇ ½ÃÀå ¼¼±×¸ÕÆ®, ÇöÀçÀÇ µ¿Çâ, ÃßÁ¤, ¿ªÇÐÀ» Á¤·®ÀûÀ¸·Î ºÐ¼®ÇÏ¿© ¿ì¼¼ÇÑ Ç÷°ü »öÀü¼ú ½ÃÀåÀÇ ±âȸ¸¦ È®ÀÎÇÕ´Ï´Ù.
  • ½ÃÀå Á¶»ç´Â ÁÖ¿ä ÃËÁø ¿äÀÎ, ½ÃÀå ¾ïÁ¦ ¿äÀÎ, ±âȸ¿Í °ü·ÃµÈ Á¤º¸¿Í ÇÔ²² Á¦°øµË´Ï´Ù.
  • Porter's Five Forces ºÐ¼®Àº ÀÌÇØ°ü°èÀÚµéÀÌ ÀÌÀÍ ÁöÇâÀûÀÎ ºñÁî´Ï½º °áÁ¤À» ³»¸®°í °ø±Þ¾÷ü¿Í ±¸¸ÅÀÚÀÇ ³×Æ®¿öÅ©¸¦ °­È­ÇÒ ¼ö ÀÖµµ·Ï ±¸¸ÅÀÚ¿Í °ø±Þ¾÷üÀÇ È¿·ÂÀ» °­Á¶ÇÕ´Ï´Ù.
  • Ç÷°ü »öÀü¼ú ½ÃÀå ¼¼ºÐÈ­ÀÇ »ó¼¼ÇÑ ºÐ¼®Àº ÀϹÝÀûÀÎ ½ÃÀå ±âȸ¸¦ °áÁ¤ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ.
  • °¢ Áö¿ªÀÇ ÁÖ¿ä ±¹°¡´Â ¼¼°è ½ÃÀå¿¡ ´ëÇÑ ¼öÀÍ °øÇåµµ¿¡ µû¶ó ¸ÅÇε˴ϴÙ.
  • ¸¶ÄÏÇ÷¹ÀÌ¾î Æ÷Áö¼Å´×Àº º¥Ä¡¸¶Å©¸¦ ¿ëÀÌÇÏ°Ô ÇÏ°í ¸¶ÄÏÇ÷¹À̾îÀÇ ÇöÀç À§Ä¡¿¡ ´ëÇÑ ¸íÈ®ÇÑ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â Áö¿ª ¹× ¼¼°è Ç÷°ü »öÀü¼úÀÇ ½ÃÀå µ¿Çâ, ÁÖ¿ä ±â¾÷, ½ÃÀå ¼¼±×¸ÕÆ®, ÀÀ¿ë ºÐ¾ß ¹× ½ÃÀå ¼ºÀå Àü·«¿¡ ´ëÇÑ ºÐ¼®À» °Ô½ÃÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä Á¶»ç °á°ú
    • ÁÖ¿ä ÅõÀÚ Æ÷ÄÏ
  • Porter's Five Forces ºÐ¼®
  • ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø ¿äÀÎ
    • ¾ïÁ¦ ¿äÀÎ
    • ±âȸ
  • COVID-19 ¿µÇ⠺м®

Á¦4Àå Ç÷°ü »öÀü¼ú ½ÃÀå : Á¦Ç°º°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • »öÀüÁ¦
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º° ºÐ¼®
    • »öÀüÁ¦ Ç÷°ü »öÀü¼ú ½ÃÀå : À¯Çüº°
      • ¾×»ó »öÀüÁ¦ÀÇ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°
      • ¸¶ÀÌÅ©·Î½ºÇǾîÀÇ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø : Áö¿ªº°
  • »öÀü¿ë µð¹ÙÀ̽º
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • »öÀü±â±¸ Ç÷°ü »öÀü¼ú ½ÃÀå : À¯Çüº°
      • ÄÚÀÏ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
      • À̵¿½Ä dz¼± ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
      • »öÀü¿ë Ç÷¯±×ÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
      • Áö¿ø µð¹ÙÀ̽ºÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°

Á¦5Àå Ç÷°ü »öÀü¼ú ½ÃÀå : Àû¿ë ºÐ¾ßº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • ¿ÂÄÝ·ÎÁö
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ¸»ÃÊ Ç÷°ü Áúȯ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ºñ´¢±â°ú¡¤½ÅÀå³»°ú
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ½Å°æÇÐ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ±âŸ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦6Àå Ç÷°ü »öÀü¼ú ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • º´¿ø°ú Ŭ¸®´Ð
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
  • ±âŸ
    • ÁÖ¿ä ½ÃÀå µ¿Çâ, ¼ºÀå ¿äÀÎ, ±âȸ
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°
    • ½ÃÀå ºÐ¼® : ±¹°¡º°

Á¦7Àå Ç÷°ü »öÀü¼ú ½ÃÀå : Áö¿ªº°

  • °³¿ä
    • ½ÃÀå ±Ô¸ð¡¤¿¹Ãø
  • ºÏ¹Ì
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ºÏ¹ÌÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
      • ºÏ¹ÌÀÇ »öÀüÁ¦¡¤Ç÷°ü »öÀü¼ú ½ÃÀå : À¯Çüº°
      • ºÏ¹ÌÀÇ Ç÷°ü »öÀü¼ú¿ë µð¹ÙÀ̽º ½ÃÀå : À¯Çüº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°
    • ºÏ¹Ì ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • À¯·´
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • À¯·´ÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
      • À¯·´ÀÇ »öÀüÁ¦ Ç÷°ü »öÀü¼ú ½ÃÀå : À¯Çüº°
      • À¯·´ÀÇ Ç÷°ü »öÀü¼ú¿ë µð¹ÙÀ̽º ½ÃÀå : À¯Çüº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°
    • À¯·´ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ¿µ±¹
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
      • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ »öÀüÁ¦ Ç÷°ü »öÀü¼ú ½ÃÀå : À¯Çüº°
      • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç÷°ü »öÀü¼ú¿ë µð¹ÙÀ̽º ½ÃÀå : À¯Çüº°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç Ç÷°ü »öÀü¼ú ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç÷°ü »öÀü¼úÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • LAMEA
    • ÁÖ¿ä µ¿Çâ°ú ±âȸ
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Á¦Ç°º°
      • LAMEA »öÀüÁ¦ Ç÷°ü »öÀü¼ú ½ÃÀå : À¯Çüº°
      • LAMEA Ç÷°ü »öÀü¼ú¿ë µð¹ÙÀ̽º ½ÃÀå : À¯Çüº°
    • LAMEA Ç÷°ü»öÀü¼úÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿ëµµº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ¿£µåÀ¯Àúº°
    • LAMEAÀÇ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ±¹°¡º°
      • ºê¶óÁú
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ³²¾ÆÇÁ¸®Ä« °øÈ­±¹
      • ±âŸ LAMEA Áö¿ª

Á¦8Àå ±â¾÷ Á¤¼¼

  • ¼Ò°³
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÁÖ¿ä 10°³»çÀÇ Á¦Ç° ¸ÅÇÎ
  • °æÀï ´ë½Ãº¸µå
  • °æÇÕÀÇ È÷Æ® ¸Ê
  • ÁÖ¿ä ¹ßÀü

Á¦9Àå ±â¾÷ ÇÁ·ÎÇÊ

  • BOSTON SCIENTIFIC CORPORATION
  • MERIT MEDICAL SYSTEMS
  • TERUMO CORPORATION
  • MEDTRONIC PLC
  • ABBOTT LABORATORIES
  • DEPUY SYNTHES(J&J MEDICAL DEVICES)
  • COOK MEDICAL
  • BALT
  • KANEKA CORPORATION
  • STRYKER CORPORATION
ksm 23.03.27

The global vascular embolization market was valued at $3,682.73 million in 2021, and is projected to reach $7,780.98 million by 2031, registering a CAGR of 7.7% from 2022 to 2031. 

A minimally invasive process called embolization inhibits blood flow in certain places. The procedure is carried out while preserving regular blood flow in the surrounding areas to protect tissues while managing problematic bleeding. When a blood vessel becomes blocked, it is called an embolism, and when a blood vessel is purposefully blocked for medical reasons, it is called an embolization operation. A catheter-based technique called coil embolization enables exact blockage of aberrant blood flow in a blood artery. An artery, typically in the groin, is entered using a catheter with a metallic occluding coil (the femoral artery). 

The aberrant blood vessel is then reached by the advancement. By moving forward with blood flow and penetrating deeper into the vascular bed to locations where a catheter or coil may not reach, liquid embolic agents have the capacity to fill the target vessel and cause vascular blockage. Detachable balloons have an advantage over other embolization techniques such as embolization through detachable balloons is reversible until the balloon is removed. Large arteries and fistulae can be instantly and precisely occluded .The growth of global vascular embolization market is majorly driven by an alarming increase in prevalence of vascular diseases. Increase in improvements in vascular disease treatment by embolization techniques and products also accelerates the growth of the vascular embolization market. 

Moreover, increased success rate of embolization plugs in non-invasive procedures for vascular occlusion, its availability as a viable alternative to conventional procedure and other technological advancement in this is anticipated to drive the market even more. To site an example, the Amplatzer Plug 4 by St. Jude Medical, Inc. is easily available in the market. However, high cost of vascular embolization, complications associated with it, hinders the growth of the market. In addition, therapies like chemotherapy, and radiation therapy are preferred options in the treatment of cancer because people are generally aware of traditional cancer treatments, advanced treatment options are not widely used and oncologists are reluctant to switch from traditional treatment options. In addition, risk of lodging an embolic agent in the wrong place can deprive normal tissues of oxygen. These are the factors which will negatively impact the growth of the market.

The global vascular embolization market is segmented into product, application, and end user. By product, the market is categorized into embolic agents and embolization devices. Embolic agents and Embolic Devices are further sub categorized into liquid embolic agents and microspheres. And embolization devices are classified into coils, detachable balloons, embolic plugs, and support devices. 

On the basis of application, the market is segregated into oncology, peripheral vascular diseases, urology and nephrology, neurology and others. On the basis of end user, the market is segmented into hospitals & clinics, ambulatory surgical centers and others. By region market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global vascular embolization market are Abbott Laboratories., Balt Group, Boston Scientific Corporation, Cook Medical, Johnson and Johnson, Kaneka Corporation, Medtronic Plc, Merit Medical, Stryker Corporation, and Terumo Medical Corporation.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vascular embolization market analysis from 2021 to 2031 to identify the prevailing vascular embolization market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vascular embolization market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vascular embolization market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Embolic Agents
    • Type
    • Liquid Embolic Agents
    • Microspheres
  • Embolization Devices
    • Type
    • Coils
    • Detachable Balloons
    • Embolic Plug
    • Support Devices

By Application

  • Oncology
  • Peripheral Vascular Diseases
  • Urology and Nephrology
  • Neurology
  • Others

By End User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • BOSTON SCIENTIFIC CORPORATION
    • MERIT MEDICAL SYSTEMS
    • TERUMO CORPORATION
    • MEDTRONIC PLC
    • ABBOTT LABORATORIES
    • DEPUY SYNTHES (J&J MEDICAL DEVICES)
    • COOK MEDICAL
    • BALT
    • KANEKA CORPORATION
    • STRYKER CORPORATION

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: VASCULAR EMBOLIZATION MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Embolic Agents
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Embolic Agents Vascular Embolization Market by Type
      • 4.2.4.1 Liquid Embolic Agents Market size and forecast, by region
      • 4.2.4.2 Microspheres Market size and forecast, by region
  • 4.3 Embolization Devices
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
    • 4.3.4 Embolization Devices Vascular Embolization Market by Type
      • 4.3.4.1 Coils Market size and forecast, by region
      • 4.3.4.2 Detachable Balloons Market size and forecast, by region
      • 4.3.4.3 Embolic Plug Market size and forecast, by region
      • 4.3.4.4 Support Devices Market size and forecast, by region

CHAPTER 5: VASCULAR EMBOLIZATION MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oncology
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Peripheral Vascular Diseases
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Urology and Nephrology
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
  • 5.5 Neurology
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
  • 5.6 Others
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market analysis by country

CHAPTER 6: VASCULAR EMBOLIZATION MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals and Clinics
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Ambulatory Surgical Centers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: VASCULAR EMBOLIZATION MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product
      • 7.2.2.1 North America Embolic Agents Vascular Embolization Market by Type
      • 7.2.2.2 North America Embolization Devices Vascular Embolization Market by Type
    • 7.2.3 North America Market size and forecast, by Application
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Product
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Product
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Product
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product
      • 7.3.2.1 Europe Embolic Agents Vascular Embolization Market by Type
      • 7.3.2.2 Europe Embolization Devices Vascular Embolization Market by Type
    • 7.3.3 Europe Market size and forecast, by Application
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Product
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Product
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Product
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Product
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Product
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Product
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product
      • 7.4.2.1 Asia-Pacific Embolic Agents Vascular Embolization Market by Type
      • 7.4.2.2 Asia-Pacific Embolization Devices Vascular Embolization Market by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Application
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Market size and forecast, by Product
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Market size and forecast, by Product
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 India
      • 7.4.5.3.1 Market size and forecast, by Product
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Market size and forecast, by Product
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Product
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by End User
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Product
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product
      • 7.5.2.1 LAMEA Embolic Agents Vascular Embolization Market by Type
      • 7.5.2.2 LAMEA Embolization Devices Vascular Embolization Market by Type
    • 7.5.3 LAMEA Market size and forecast, by Application
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Product
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Product
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Product
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Product
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 BOSTON SCIENTIFIC CORPORATION
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 MERIT MEDICAL SYSTEMS
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 TERUMO CORPORATION
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 MEDTRONIC PLC
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 ABBOTT LABORATORIES
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 DEPUY SYNTHES (J&J MEDICAL DEVICES)
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 COOK MEDICAL
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 BALT
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 KANEKA CORPORATION
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 STRYKER CORPORATION
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦